No Dose Adjustment Required for Omeprazole 20 mg
Omeprazole 20 mg does not require dose adjustment in this 88-year-old patient with an eGFR of 28 mL/min/1.73 m².
Rationale Based on FDA Drug Label
Omeprazole is primarily metabolized hepatically through the cytochrome P450 system (CYP2C19 and CYP3A4), not renally eliminated 1. The FDA label explicitly states: "In patients with chronic renal impairment (creatinine clearance between 10 and 62 mL/min/1.73 m²), the disposition of omeprazole was very similar to that in healthy subjects, although there was a slight increase in bioavailability" 1. Critically, the label concludes: "This increase in bioavailability is not considered to be clinically meaningful" 1.
Pharmacokinetic Considerations
- Metabolism: Omeprazole undergoes extensive hepatic metabolism via CYP2C19 (forming hydroxyomeprazole) and CYP3A4 (forming omeprazole sulphone) 1
- Renal excretion: Following oral administration, little to no unchanged drug is excreted in urine; approximately 77% is eliminated as metabolites in urine, with the remainder in feces 1
- Metabolite accumulation: While metabolite elimination slows proportionally with decreased creatinine clearance, these metabolites have "very little or no antisecretory activity" 1
Research confirms minimal renal clearance, with one study showing urinary excretion of only 6.71% of the dose 2.
Age-Related Considerations
The patient's advanced age (88 years) does warrant attention, but for different reasons than renal function. The FDA label notes that in elderly patients, omeprazole bioavailability increases to 76% (versus 58% in young volunteers) and plasma clearance decreases to approximately 250 mL/min (half that of young volunteers) 1. However, no specific dose adjustment recommendations are provided for elderly patients in the drug label 1.
The European Society of Cardiology guidelines emphasize that drug accumulation due to reduced renal excretion is most important for renally cleared drugs 3. Since omeprazole is hepatically cleared, this concern does not apply here.
Clinical Monitoring
While no dose adjustment is needed, monitor for:
- Drug interactions: Omeprazole is a time-dependent CYP2C19 inhibitor and can increase exposure to drugs metabolized by this pathway 1
- General tolerability: The patient's age and potential frailty may increase susceptibility to adverse effects unrelated to renal function
- Polypharmacy concerns: At 88 years old, review all medications for appropriateness 3
Common Pitfall to Avoid
Do not confuse omeprazole with renally cleared proton pump inhibitors or assume all medications require renal dose adjustment in CKD. The key is understanding the primary route of elimination. Omeprazole's hepatic metabolism makes it safe at standard doses even with eGFR 28 mL/min/1.73 m² 1.